Effect of Upadacitinib on Atopic Hand Eczema in Patients With Moderate-to-Severe Atopic Dermatitis: Results From Two Randomised Phase 3 Trials.
Eric L SimpsonK RahawiX HuA D ChuC NduakaS JazayeriPeter A LioC LyndeM L A SchuttelaarPublished in: Journal of the European Academy of Dermatology and Venereology : JEADV (2023)
Upadacitinib 15 mg and 30 mg monotherapy provided rapid and sustained improvement in atopic hand eczema compared to placebo through week 16 in patients with moderate-to-severe AD. At week 16, the observed mean improvements in HECSI score in upadacitinib-treated patients were clinically meaningful based on previous interpretability studies. These results suggest that upadacitinib may be an effective treatment option for atopic hand eczema in patients with moderate-to-severe AD.